Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection

Nephrology

Volumn 16, Issue 2, 2011, Pages 239-242

  Huang, Louis ^a   Kanellis, John ^a,b   Mulley, William ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

antibody mediated rejection; intravenous immunoglobulin; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; IMMUNOGLOBULIN G; INFUSION FLUID; PREDNISOLONE; WARFARIN;

ADULT; ANTIBODY MEDIATED REJECTION; ANTICOAGULANT THERAPY; ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING; CLINICAL PROTOCOL; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG DOSE INCREASE; DRUG INFUSION; DRUG MEGADOSE; FEMALE; FLUID OVERLOAD; GRAFT RECIPIENT; HEART INFARCTION; HUMAN; HYDRATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEG THROMBOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RENAL ARTERY THROMBOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; THROMBOSIS PREVENTION; TREATMENT DURATION; VEIN THROMBOSIS;

ANTICOAGULANTS; ASPIRIN; ENOXAPARIN; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 79551515520     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01399.x     Document Type: Article

References (20)

1. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800-5.
2. Jurisdictional Blood Committee, for and on behalf of the Health Minister's Conference. Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia. Canberra: Commonwealth of Australia. 2007; 6: 160.
3. Shehata N, Palda VA, Meyer RM,. et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: An evidence-based practice guideline. Transfus. Med. Rev. 2010; 24 (Suppl 1): S7-27.
4. Wittstock M, Zettl UK,. Adverse effects of treatment with intravenous immunoglobulins for neurological diseases. J. Neurol. 2005; 253 (Suppl 5): V/75-9.
5. Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R,. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul. Fibrinolysis 2005; 16: 313-18.
6. Marie I, Maurey G, Hervé F, Hellot MF, Levesque H,. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br. J. Dermatol. 2006; 155: 714-21.
7. Katz U, Shoenfeld Y,. Review: Intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005; 14: 802-8.
8. Tufan F, Kamali S, Erer B, et al. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clin. Rheumatol. 2007; 26: 1913-15.
9. Gloor J, Cosio F, Lager DJ, Stegall MD,. The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Am. J. Transplant. 2008; 8: 1367-73.
10. Mai ML, Ahsan N, Wadei HM, et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009; 87: 227-32.
11. Sener A, House AA, Jevnikar AM, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: One-year follow-up of renal allograft recipients. Transplantation 2006; 81: 117-20.
12. Woodruff RK, Grigg AP, Firkin FC, Smith IL,. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986; 2: 217-18.
13. Caress JB, Hobson-Webb L, Passmore LV, Finkbiner AP, Cartwright MS,. Case-control study of thromboembolic events associated with IV immunoglobulin. J. Neurol. 2009; 256: 339-42.
14. Feuillet L, Guedj E, Laskiri N, et al. Deep vein thrombosis after intravenous immunoglobulins associated with methylprednisolone. Thromb. Haemost. 2004; 92: 662-5.
15. Dalakas MC,. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology 1994; 44: 223-6.
16. Reinhart WH, Berchtold PE,. Effect of high-dose intravenous immuno-globulin therapy on blood rheology. Lancet 1992; 339: 662-4.
17. Wolberg AS, Kon RH, Monroe DM, Hoffman M,. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am. J. Hematol. 2000; 65: 30-34.
18. Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R,. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin. Neurology 1996; 46: 250-51.
19. Sztajzel R, Le Floch-Rohr J, Eggimann P,. High dose intravenous immunoglobulin treatment and cerebral vasospasm: A possible mechanism of ischemic encephalopathy? Eur. Neurol. 1999; 41: 153-8.
20. Mignogna MD, Fortuna G, Leuci S, Ruoppo E, Adamo D, Fedele S,. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: A preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases. Clin. Exp. Dermatol. 2008; 34: 145-50.